In this prospective single-center study, migalastat’s efficacy and biomarkers changes were evaluated after 1 year of treatment for 14 FD patients (mean age of 55 ± 14 years); six of these patients were from the group that switched from ERT (agalsidase alfa 0.2 mg/kg or agalsidase beta 1 mg/kg) to migalastat. The gene discussed is GLA; the disease is Fabry disease.